- Home
- GILD vs V Comparison
GILD vs V Comparison
Compare GILD & V Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | V |
|---|---|---|
| Founded | 1987 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.5B | 676.2B |
| IPO Year | 2000 | 2007 |
Fundamental Metrics
Financial Performance| Metric | GILD | V |
|---|---|---|
| Price | $148.38 | $314.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 20 |
| Target Price | $143.50 | ★ $399.20 |
| AVG Volume (30 Days) | 6.3M | ★ 7.0M |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.28% | 0.84% |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | ★ 6.78 | N/A |
| Revenue | ★ $24,689,000,000.00 | $21,846,000,000.00 |
| Revenue This Year | $4.68 | $13.81 |
| Revenue Next Year | $6.10 | $10.27 |
| P/E Ratio | ★ $21.23 | $30.09 |
| Revenue Growth | ★ 9.98 | N/A |
| 52 Week Low | $95.30 | $299.00 |
| 52 Week High | $157.29 | $375.51 |
Technical Indicators
Market Signals| Indicator | GILD | V |
|---|---|---|
| Relative Strength Index (RSI) | 55.45 | 41.90 |
| Support Level | $143.09 | $304.57 |
| Resistance Level | $157.29 | $350.70 |
| Average True Range (ATR) | 3.15 | 6.51 |
| MACD | -1.11 | 0.51 |
| Stochastic Oscillator | 57.99 | 48.77 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About V Visa Inc.
Visa is the largest payment processor in the world. In fiscal 2025, it processed almost $17 trillion in total volume. Visa operates in over 200 countries and processes transactions in over 160 currencies. Its systems are capable of processing over 65,000 transactions per second.